ORIC Pharmaceuticals, Inc. (ORIC) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ORIC Pharamceuticals (ORIC) PT Raised to $17 at Oppenheimer, 'Executing On Multiple Fronts'
March 12, 2024 9:21 AM EDTOppenheimer analyst Matthew Biegler raised the price target on ORIC Pharamceuticals (NASDAQ: ORIC) to $17.00 (from $14.00) while maintaining a Outperform rating.
The analyst comments "Monday, ORIC reported 2023 financials. We are pleased with managements execution, adding in strategic financings on the heels of... More
